{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:10:37Z","timestamp":1795043437614,"version":"4.10.2"},"reference-count":240,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008402","name":"Chengdu University of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008402","name":"Chengdu University of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.biopha.2021.111561","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T14:15:22Z","timestamp":1618323322000},"page":"111561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":127,"special_numbering":"C","title":["Pharmacological and clinical application of heparin progress: An essential drug for modern medicine"],"prefix":"10.1016","volume":"139","author":[{"given":"Min","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binzhu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haozhou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Ci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingkun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.111561_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmbts.2019.02.002","article-title":"Heparin: an essential drug for modern medicine","volume":"163","author":"Hao","year":"2019","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2021.111561_bib2","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s11239-015-1261-z","article-title":"Heparin: 100 years of pleiotropic effects","volume":"41","author":"Paschoa","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib3","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3892\/ijo.2014.2803","article-title":"Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models","volume":"46","author":"Alyahya","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/pr.115.011247","article-title":"Pharmacology of heparin and related drugs","volume":"68","author":"Mulloy","year":"2016","journal-title":"Pharm. Rev."},{"issue":"12","key":"10.1016\/j.biopha.2021.111561_bib5","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1111\/jth.14317","article-title":"Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer","volume":"16","author":"Van Matre","year":"2018","journal-title":"J. Thromb. Haemost. JTH"},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5582\/ddt.8.1","article-title":"Pharmacological effects and clinical applications of ultra low molecular weight heparins","volume":"8","author":"Liu","year":"2014","journal-title":"Drug Discov. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2019.140301","article-title":"Chemoenzymatic synthesis of ultralow and low-molecular weight heparins","volume":"1868","author":"Wang","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA) Proteins Proteom."},{"key":"10.1016\/j.biopha.2021.111561_bib8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.carres.2014.06.023","article-title":"Re-visiting the structure of heparin","volume":"403","author":"Casu","year":"2015","journal-title":"Carbohydr. Res."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2013.06.007","article-title":"Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer","volume":"88","author":"Walenga","year":"2013","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"issue":"13","key":"10.1016\/j.biopha.2021.111561_bib10","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1021\/jm030176m","article-title":"2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity","volume":"46","author":"Linhardt","year":"2003","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib11","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.thromres.2011.11.008","article-title":"Old and new heparins","volume":"129","author":"Cosmi","year":"2012","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/btm2.10042","article-title":"Engineered heparins as new anticoagulant drugs","volume":"2","author":"Vaidyanathan","year":"2017","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.biopha.2021.111561_bib13","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2741\/4462","article-title":"Heparin and anticoagulation","volume":"21","author":"Onishi","year":"2016","journal-title":"Front. Biosci. (Landmark Ed.)"},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4155\/fmc.11.185","article-title":"Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics","volume":"4","author":"Masuko","year":"2012","journal-title":"Future Med. Chem."},{"issue":"6055","key":"10.1016\/j.biopha.2021.111561_bib15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1126\/science.1207478","article-title":"Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins","volume":"334","author":"Xu","year":"2011","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.biopha.2021.111561_bib16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.thromres.2010.12.009","article-title":"Safety assessment and pharmacodynamics of a novel ultra low molecular weight heparin (RO-14) in healthy volunteers--a first-time-in-human single ascending dose study","volume":"127","author":"Rico","year":"2011","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.biopha.2021.111561_bib17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.5301\/hipint.5000039","article-title":"Postoperative plasma D-dimer value for predicting deep venous thrombosis following hip arthroplasty with nadroparin prophylaxis","volume":"23","author":"Xu","year":"2013","journal-title":"Hip Int."},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib18","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1089\/jop.2012.0012","article-title":"Subcutaneous nadroparin calcium in the treatment of recent onset retinal vein occlusion: a pilot study","volume":"28","author":"Pinna","year":"2012","journal-title":"J. Ocul. Pharm. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/1076029611429123","article-title":"The influence of decreased low-molecular-weight heparin nadroparin dose on diastolic blood pressure in patients on hemodialysis","volume":"18","author":"Sain","year":"2012","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1078155209353465","article-title":"Successful administration of a low dose of calcium nadroparin in patients suffering from pulmonary embolism and brain metastases: a report of two cases","volume":"17","author":"Vitale","year":"2011","journal-title":"J. Oncol. Pharm. Pract. Off. Publ. Int. Soc. Oncol. Pharm. Pract."},{"key":"10.1016\/j.biopha.2021.111561_bib21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.carbpol.2014.01.100","article-title":"A world of low molecular weight heparins (LMWHs) enoxaparin as a promising moiety--a review","volume":"106","author":"Ingle","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.biopha.2021.111561_bib22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.tvjl.2014.03.032","article-title":"Enoxaparin: pharmacokinetics and treatment schedule for cats","author":"Mischke","year":"2014","journal-title":"Vet. J."},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1024\/0301-1526\/a000338","article-title":"Effects of enoxaparin and dalteparin on proliferation and migration of patient-derived vascular smooth muscle cells","volume":"43","author":"Ellensen","year":"2014","journal-title":"VASA Z. Gefasskrankh."},{"key":"10.1016\/j.biopha.2021.111561_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2014.03.002","article-title":"Development and evaluation of PEGylated enoxaparin: a novel approach for enhanced anti-Xa activity","volume":"54","author":"Choubey","year":"2014","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3944\/AOTT.2014.13.0075","article-title":"Effects of enoxaparin and rivaroxaban on tissue survival in skin degloving injury: an experimental study","volume":"48","author":"Azboy","year":"2014","journal-title":"Acta Orthop. Traumatol. Turc."},{"issue":"6","key":"10.1016\/j.biopha.2021.111561_bib26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.4318\/tjg.2013.0585","article-title":"Preventive effects of enoxaparin and hesperidin in cerulein-induced acute pancreatitis in rats","volume":"24","author":"K\u00f6ksoy","year":"2013","journal-title":"Turk. J. Gastroenterol. Off. J. Turk. Soc. Gastroenterol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111561_bib27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.thromres.2013.10.005","article-title":"Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms","volume":"132","author":"Rojas","year":"2013","journal-title":"Thromb. Res."},{"key":"10.1016\/j.biopha.2021.111561_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2431-14-27","article-title":"Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study","volume":"14","author":"Inamo","year":"2014","journal-title":"BMC Pediatr."},{"key":"10.1016\/j.biopha.2021.111561_bib29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000356384","article-title":"Pharmacokinetics of dalteparin during haemodialysis","volume":"124","author":"Nigten","year":"2013","journal-title":"Nephron Clin. Pract."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2021.111561_bib30","first-page":"53","article-title":"Dalteparin dosing in high-flux haemodialysis and haemodiafiltration","volume":"122","author":"Sridharan","year":"2012","journal-title":"Nephron Clin. Pract."},{"issue":"12","key":"10.1016\/j.biopha.2021.111561_bib31","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/j.1600-0463.2010.02635.x","article-title":"Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo","volume":"118","author":"Norrby","year":"2010","journal-title":"APMIS Acta Pathol. Microbiol. Immunol. Scand."},{"issue":"14","key":"10.1016\/j.biopha.2021.111561_bib32","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa1014475","article-title":"Dalteparin versus unfractionated heparin in critically ill patients","volume":"364","author":"Cook","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1053\/j.ajkd.2012.01.020","article-title":"Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial","volume":"60","author":"Rodger","year":"2012","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"issue":"Suppl. 5 (Pt. 2)","key":"10.1016\/j.biopha.2021.111561_bib34","first-page":"S603","article-title":"Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects","volume":"58","author":"Scheuch","year":"2007","journal-title":"J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib35","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/1076029612449899","article-title":"Prospective, non-interventional study on the real-world use of certoparin in daily practice--the PROMEMBER study","volume":"19","author":"Spannagl","year":"2013","journal-title":"Clin. Appl. Thromb.\/Hemost. Off. J. Int. Acad. Clin. Appl. Thromb.\/Hemost."},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib36","doi-asserted-by":"crossref","first-page":"R541","DOI":"10.1186\/cc3792","article-title":"Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study","volume":"9","author":"Jochberger","year":"2005","journal-title":"Crit. Care"},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1517\/13543784.8.3.315","article-title":"Pharmacologic profile of certoparin","volume":"8","author":"Jeske","year":"1999","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib38","first-page":"1092","article-title":"Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin","volume":"29","author":"Pauwels","year":"2014","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib39","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/MAT.0b013e31824c38c8","article-title":"Tinzaparin is safe and effective in the management of hemodialysis catheter thrombosis","volume":"58","author":"Quinlan","year":"2012","journal-title":"ASAIO J."},{"issue":"13","key":"10.1016\/j.biopha.2021.111561_bib40","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2165\/00003495-200464130-00006","article-title":"Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease","volume":"64","author":"Cheer","year":"2004","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.biopha.2021.111561_bib41","first-page":"833","article-title":"Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparin","volume":"90","author":"Maugeri","year":"2005","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11739-010-0479-1","article-title":"Low molecular weight heparin (parnaparin) for cardioembolic events prevention in patients with atrial fibrillation undergoing elective electrical cardioversion: a prospective cohort study","volume":"6","author":"Angeloni","year":"2011","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.biopha.2021.111561_bib43","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2147\/VHRM.S3430","article-title":"Update on the clinical use of the low-molecular-weight heparin, parnaparin","volume":"5","author":"Camporese","year":"2009","journal-title":"Vasc. Health Risk Manag."},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib44","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2147\/VHRM.S3253","article-title":"Clinical use of parnaparin in major and minor orthopedic surgery: a review","volume":"4","author":"Bugamelli","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"issue":"6","key":"10.1016\/j.biopha.2021.111561_bib45","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1160\/TH06-12-0680","article-title":"Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood","volume":"97","author":"Maugeri","year":"2007","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.biopha.2021.111561_bib46","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2165\/00003495-199447040-00007","article-title":"Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders","volume":"47","author":"Frampton","year":"1994","journal-title":"Drugs"},{"issue":"Suppl. 2","key":"10.1016\/j.biopha.2021.111561_bib47","first-page":"43","article-title":"New frontiers with bemiparin: use in special populations","volume":"70","author":"Fontcuberta Boj","year":"2010","journal-title":"Drugs"},{"issue":"Suppl. 2","key":"10.1016\/j.biopha.2021.111561_bib48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/1158584-S0-000000000-00000","article-title":"Clinical experience with bemiparin","volume":"70","author":"Abad Rico","year":"2010","journal-title":"Drugs"},{"issue":"Suppl. 2","key":"10.1016\/j.biopha.2021.111561_bib49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/1158581-S0-000000000-00000","article-title":"Bemiparin: pharmacological profile","volume":"70","author":"S\u00e1nchez-Ferrer","year":"2010","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib50","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1586\/erc.10.35","article-title":"New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin","volume":"8","author":"Mart\u00ednez-Gonz\u00e1lez","year":"2010","journal-title":"Expert Rev. Cardiovasc. Ther."},{"issue":"2\u20133","key":"10.1016\/j.biopha.2021.111561_bib51","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ejphar.2008.11.042","article-title":"Bemiparin improves the total antioxidant status in plasma","volume":"602","author":"Garc\u00eda-de-la-Asunci\u00f3n","year":"2009","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111561_bib52","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1586\/14779072.6.6.793","article-title":"Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism","volume":"6","author":"Mart\u00ednez-Gonz\u00e1lez","year":"2008","journal-title":"Expert Rev. Cardiovasc. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib53","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1586\/14737167.6.3.249","article-title":"Cost-effectiveness of bemiparin in the prevention and treatment of venous thromboembolism","volume":"6","author":"G\u00f3mez-Outes","year":"2006","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.vph.2014.03.001","article-title":"Bemiparin, an effective and safe low molecular weight heparin: a review","volume":"62","author":"Ciccone","year":"2014","journal-title":"Vasc. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib55","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ab.2011.11.021","article-title":"Fluorescent reporters of thrombin, heparin cofactor II, and heparin binding in a ternary complex","volume":"421","author":"Verhamme","year":"2012","journal-title":"Anal. Biochem."},{"issue":"9","key":"10.1016\/j.biopha.2021.111561_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2020.100648","article-title":"Coagulopathy and plausible benefits of anticoagulation among COVID-19 patients","volume":"45","author":"Ahmed","year":"2020","journal-title":"Curr. Probl. Cardiol."},{"issue":"52","key":"10.1016\/j.biopha.2021.111561_bib57","doi-asserted-by":"crossref","first-page":"50756","DOI":"10.1074\/jbc.M208485200","article-title":"Localization of the heparin binding exosite of factor IXa","volume":"277","author":"Yang","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.biopha.2021.111561_bib58","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.biochi.2010.05.011","article-title":"Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors","volume":"92","author":"Olson","year":"2010","journal-title":"Biochimie"},{"issue":"16","key":"10.1016\/j.biopha.2021.111561_bib59","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1080\/07391102.2019.1688194","article-title":"The mechanism of high affinity pentasaccharide binding to antithrombin, insights from Gaussian accelerated molecular dynamics simulations","volume":"38","author":"Balogh","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.biopha.2021.111561_bib60","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fmed.2019.00254","article-title":"Heparins: a shift of paradigm","volume":"6","author":"Hemker","year":"2019","journal-title":"Front. Med."},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib61","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/jth.13198","article-title":"Identification and function probing of an antithrombin III\u03b2 conformation-specific antibody","volume":"14","author":"Jin","year":"2016","journal-title":"J. Thromb. Haemost."},{"issue":"15","key":"10.1016\/j.biopha.2021.111561_bib62","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1021\/acs.biochem.8b00216","article-title":"Cooperative interactions of three hotspot heparin binding residues are critical for allosteric activation of antithrombin by heparin","volume":"57","author":"Richard","year":"2018","journal-title":"Biochemistry"},{"issue":"04","key":"10.1016\/j.biopha.2021.111561_bib63","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-0031-1276582","article-title":"Heparin cofactor II: discovery, properties, and role in controlling vascular homeostasis","volume":"37","author":"Rau","year":"2011","journal-title":"Semin. Thromb. Hemost."},{"issue":"4","key":"10.1016\/j.biopha.2021.111561_bib64","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/jth.14401","article-title":"Sodium-site in serine protease domain of human coagulation factor IXa: evidence from the crystal structure and molecular dynamics simulations study","volume":"17","author":"Vadivel","year":"2019","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib65","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1538-7836.2011.04605.x","article-title":"Correlation of factor IXa subsite modulations with effects on substrate discrimination","volume":"10","author":"Neuenschwander","year":"2012","journal-title":"J. Thromb. Haemost. JTH"},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib66","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1160\/TH09-08-0585","article-title":"Contribution of exosite occupancy by heparin to the regulation of coagulation proteases by antithrombin","volume":"103","author":"Yang","year":"2010","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.biopha.2021.111561_bib67","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.13005","article-title":"Factor XI and contact activation as targets for antithrombotic therapy","volume":"13","author":"Gailani","year":"2015","journal-title":"J. Thromb. Haemost. JTH"},{"key":"10.1016\/j.biopha.2021.111561_bib68","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2017.10.008","article-title":"An update on factor XI structure and function","volume":"161","author":"Mohammed","year":"2018","journal-title":"Thromb. Res."},{"issue":"12","key":"10.1016\/j.biopha.2021.111561_bib69","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1111\/jth.14606","article-title":"A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding","volume":"17","author":"Al-Horani","year":"2019","journal-title":"J. Thromb. Haemost. JTH"},{"issue":"13","key":"10.1016\/j.biopha.2021.111561_bib70","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1016\/S0021-9258(18)68737-X","article-title":"Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains","volume":"263","author":"Wun","year":"1988","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib71","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1055\/s-0037-1614416","article-title":"TFPIbeta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene","volume":"81","author":"Chang","year":"1999","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib72","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1161\/01.CIR.0000078642.45127.7B","article-title":"Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor","volume":"108","author":"Zhang","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib73","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1160\/th15-04-0354","article-title":"Role of exosite binding modulators in the inhibition of Fxa by TFPI","volume":"115","author":"Peraramelli","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.biopha.2021.111561_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143137","article-title":"Phospholipid binding protein C inhibitor (PCI) is present on microparticles generated in vitro and in vivo","volume":"10","author":"Einfinger","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.biopha.2021.111561_bib75","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1073\/pnas.0711055105","article-title":"Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-A structure of the heparin-bridged complex","volume":"105","author":"Li","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib76","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1160\/TH13-06-0478","article-title":"New lipid interaction partners stimulate the inhibition of activated protein C by cell-penetrating protein C inhibitor","volume":"111","author":"Wahlm\u00fcller","year":"2014","journal-title":"Thromb. Haemost."},{"issue":"51","key":"10.1016\/j.biopha.2021.111561_bib77","doi-asserted-by":"crossref","first-page":"36039","DOI":"10.1074\/jbc.M805974200","article-title":"The heparin binding site of protein C inhibitor is protease-dependent","volume":"283","author":"Li","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2021.111561_bib78","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1007\/s13277-015-3117-8","article-title":"Significantly inhibitory effects of low molecular weight heparin (Fraxiparine) on the motility of lung cancer cells and its related mechanism","volume":"36","author":"Zhong","year":"2015","journal-title":"Tumour Biol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191303","article-title":"The mechanisms how heparin affects the tumor cell induced VEGF and chemokine release from platelets to attenuate the early metastatic niche formation","volume":"13","author":"Ponert","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biopha.2021.111561_bib80","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.thromres.2006.10.026","article-title":"The anti-inflammatory effects of heparin and related compounds","volume":"122","author":"Young","year":"2008","journal-title":"Thromb. Res."},{"issue":"7","key":"10.1016\/j.biopha.2021.111561_bib81","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0161-5890(93)90079-Q","article-title":"Identification of multiple sites of interaction between heparin and the complement system","volume":"30","author":"Sahu","year":"1993","journal-title":"Mol. Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2021.111561_bib82","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/jir.2018.0042","article-title":"Unfractionated heparin modulates lipopolysaccharide-induced cytokine production by different signaling pathways in THP-1 cells","volume":"38","author":"Li","year":"2018","journal-title":"J. Interferon Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res."},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib83","first-page":"405","article-title":"Unfractionated heparin ameliorates lipopolysaccharide induced expressions of nitric oxide and reactive oxygen species in renal microvascular endothelial cells","volume":"30","author":"Li","year":"2018","journal-title":"Zhonghua wei zhong Bing. ji jiu yi xue"},{"key":"10.1016\/j.biopha.2021.111561_bib84","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.antiviral.2015.01.008","article-title":"Heparin octasaccharide decoy liposomes inhibit replication of multiple viruses","volume":"116","author":"Hendricks","year":"2015","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib85","doi-asserted-by":"crossref","first-page":"L211","DOI":"10.1152\/ajplung.00199.2020","article-title":"Heparin as a therapy for COVID-19: current evidence and future possibilities","volume":"319","author":"Hippensteel","year":"2020","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.biopha.2021.111561_bib86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.antiviral.2016.12.023","article-title":"Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells","volume":"140","author":"Ghezzi","year":"2017","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib87","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0166-3542(94)90041-8","article-title":"Mechanism of inhibitory effect of dextran sulfate and heparin on human T-cell lymphotropic virus type I (HTLV-I)-induced syncytium formation in vitro: role of cell-to-cell contact","volume":"23","author":"Ida","year":"1994","journal-title":"Antivir. Res."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2021.111561_bib88","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11010-011-1078-9","article-title":"Regulation of PMA-induced MUC5AC expression by heparin in human bronchial epithelial cells","volume":"360","author":"Li","year":"2012","journal-title":"Mol. Cell. Biochem."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib89","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1167\/iovs.61.3.24","article-title":"TGF\u03b22-hepcidin feed-forward loop in the trabecular meshwork implicates iron in glaucomatous pathology","volume":"61","author":"Ashok","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2021.111561_bib90","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/08860220600925594","article-title":"Acute effect of standard heparin versus low molecular weight heparin on oxidative stress and inflammation in hemodialysis patients","volume":"28","author":"Poyrazoglu","year":"2006","journal-title":"Ren. Fail."},{"key":"10.1016\/j.biopha.2021.111561_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113867","article-title":"Pentosan polysulfate to control hepcidin expression in vitro and in vivo","volume":"175","author":"Asperti","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"22","key":"10.1016\/j.biopha.2021.111561_bib92","first-page":"1831","article-title":"Promising novel applications of heparin","volume":"54","author":"Zhang","year":"2019","journal-title":"Chin. Pharm. J."},{"issue":"4","key":"10.1016\/j.biopha.2021.111561_bib93","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3892\/etm.2013.965","article-title":"A clinical study of transcranial ultrasound as an adjuvant therapy for progressive cerebral infarction","volume":"5","author":"Gao","year":"2013","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib94","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/jcpt.12763","article-title":"Effects of six types of aspirin combination medications for treatment of acute cerebral infarction in China: a network meta-analysis","volume":"44","author":"Jin","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"issue":"03","key":"10.1016\/j.biopha.2021.111561_bib95","first-page":"16","article-title":"Clinical observation of low molecular weight heparin calcium combined with hydroxyethyl starch in the treatment of progressive cerebral infarction","volume":"18","author":"Jia","year":"2018","journal-title":"Pract. Clin. J. Integr. Tradit. Chin. West. Med."},{"issue":"05","key":"10.1016\/j.biopha.2021.111561_bib96","first-page":"28","article-title":"Efficacy of agatroban and low-molecular-weight heparin calcium on large artery atherosclerosis progressive cerebral infarction","volume":"32","author":"Tu","year":"2019","journal-title":"Acta Med. Sin."},{"key":"10.1016\/j.biopha.2021.111561_bib97","unstructured":"Guidelines for rational drug use in coronary heart disease (the second edition), Chin. J. Front. Med. Sci. (Electronic Version), 10(06), 2018, pp. 1\u2013130."},{"key":"10.1016\/j.biopha.2021.111561_bib98","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1093\/eurheartj\/ehaa624","article-title":"The \u2018Ten Commandments\u2019 for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"41","author":"Collet","year":"2020","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib99","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2021.111561_bib100","unstructured":"Guidelines for rational use of thrombolytic therapy in patients with acute ST segment elevation myocardial infarction (the second edition), Chin. J. Front. Med. Sci. (Electronic Version), 11(01), 2019, pp. 40\u201365."},{"issue":"6","key":"10.1016\/j.biopha.2021.111561_bib101","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.006084","volume":"11","author":"Dillinger","year":"2018","journal-title":"Circ. Cardiovasc. Interv."},{"issue":"9219","key":"10.1016\/j.biopha.2021.111561_bib102","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis","volume":"355","author":"Eikelboom","year":"2000","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.biopha.2021.111561_bib103","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.jacc.2006.05.058","article-title":"A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes","volume":"48","author":"Cohen","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"issue":"37","key":"10.1016\/j.biopha.2021.111561_bib104","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.biopha.2021.111561_bib105","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/CIR.0000000000000336","volume":"133","author":"Levine","year":"2016","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.biopha.2021.111561_bib106","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","article-title":"Bivalirudin versus heparin monotherapy in myocardial infarction","volume":"377","author":"Erlinge","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib107","doi-asserted-by":"crossref","first-page":"278","DOI":"10.14740\/cr921","article-title":"Bivalirudin versus heparin during percutaneous coronary intervention in patients with acute myocardial infarction","volume":"10","author":"Patel","year":"2019","journal-title":"Cardiol. Res."},{"key":"10.1016\/j.biopha.2021.111561_bib108","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2174\/1874192401610010122","article-title":"Heparin versus bivalirudin in acute myocardial infarction: unfractionated heparin monotherapy elevated to primary treatment in contemporary percutaneous coronary intervention","volume":"10","author":"Centuri\u00f3n","year":"2016","journal-title":"Open Cardiovasc. Med. J."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib109","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2017-000767","article-title":"Bivalirudin versus heparin in primary PCI: clinical outcomes and cost analysis","volume":"5","author":"Deharo","year":"2018","journal-title":"Open Heart"},{"issue":"12","key":"10.1016\/j.biopha.2021.111561_bib110","first-page":"E387","article-title":"Periprocedural bivalirudin versus unfractionated heparin during percutaneous coronary intervention following fibrinolysis for ST-segment elevation myocardial infarction","volume":"31","author":"Rashid","year":"2019","journal-title":"J. Invasive Cardiol."},{"issue":"9792","key":"10.1016\/j.biopha.2021.111561_bib111","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","article-title":"Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial","volume":"378","author":"Montalescot","year":"2011","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.biopha.2021.111561_bib112","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.4103\/0366-6999.243559","article-title":"Unfractionated heparin with sequential enoxaparin in patients with complex coronary artery lesions during percutaneous coronary intervention","volume":"131","author":"Li","year":"2018","journal-title":"Chin. Med. J."},{"issue":"6","key":"10.1016\/j.biopha.2021.111561_bib113","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40256-018-0294-z","article-title":"Biomarkers of thrombosis in ST-segment elevation myocardial infarction: a substudy of the ATOLL trial comparing enoxaparin versus unfractionated heparin","volume":"18","author":"Silvain","year":"2018","journal-title":"Am. J. Cardiovasc. Drug Drug Devices Other Interv."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib114","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/ATVBAHA.108.162545","article-title":"The epidemiology of venous thromboembolism in the community","volume":"28","author":"Heit","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2021.111561_bib115","first-page":"756","article-title":"Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality","volume":"98","author":"Cohen","year":"2007","journal-title":"Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.biopha.2021.111561_bib116","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/imj.14063","article-title":"Update on diagnosis and anticoagulant therapy for venous thromboembolism","volume":"48","author":"Stevens","year":"2018","journal-title":"Intern. Med. J."},{"issue":"22","key":"10.1016\/j.biopha.2021.111561_bib117","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib118","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/bjh.16010","article-title":"The National VTE Exemplar Centres Network response to implementation of updated NICE guidance: venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)","volume":"186","author":"Gee","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.biopha.2021.111561_bib119","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.3390\/jcm8122039","article-title":"Low dose low-molecular-weight heparin for thrombosis prophylaxis: systematic review with meta-analysis and trial sequential analysis","volume":"8","author":"Eck","year":"2019","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.biopha.2021.111561_bib120","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.0007-1323.2001.01800.x","article-title":"Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery","volume":"88","author":"Mismetti","year":"2001","journal-title":"Br. J. Surg."},{"issue":"6","key":"10.1016\/j.biopha.2021.111561_bib121","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1258\/jrsm.2010.100086","article-title":"NICE guidance on reducing the risk of venous thromboembolism in patients admitted to hospital","volume":"103","author":"Treasure","year":"2010","journal-title":"J. R. Soc. Med."},{"issue":"12","key":"10.1016\/j.biopha.2021.111561_bib122","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/cncr.21496","article-title":"Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study","volume":"104","author":"Khorana","year":"2005","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2021.111561_bib123","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","article-title":"Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis","volume":"18","author":"Lyman","year":"2013","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib124","first-page":"40","article-title":"The incidence of venous thromboembolism in cancer patients: a real-world analysis","volume":"10","author":"Lyman","year":"2012","journal-title":"Clin. Adv. Hematol. Oncol. H&O"},{"key":"10.1016\/j.biopha.2021.111561_bib125","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22050724","article-title":"Heparin and heparin-derivatives in post-subarachnoid hemorrhage brain injury: a multimodal therapy for a multimodal disease","author":"Hayman","year":"2017","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.biopha.2021.111561_bib126","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/neurintsurg-2016-012925","article-title":"Effect of heparin on secondary brain injury in patients with subarachnoid hemorrhage: an additional \u2018H\u2019 therapy in vasospasm treatment","volume":"9","author":"Bruder","year":"2017","journal-title":"J. Neurointerv. Surg."},{"issue":"19 Pt 1","key":"10.1016\/j.biopha.2021.111561_bib127","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-05-1131","article-title":"Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity","volume":"11","author":"Stevenson","year":"2005","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"30","key":"10.1016\/j.biopha.2021.111561_bib128","doi-asserted-by":"crossref","first-page":"9104","DOI":"10.1021\/bi060338r","article-title":"New insights into the inhibition of human neutrophil elastase by heparin","volume":"45","author":"Spencer","year":"2006","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.biopha.2021.111561_bib129","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128803","article-title":"Non-anticoagulant fractions of enoxaparin suppress inflammatory cytokine release from peripheral blood mononuclear cells of allergic asthmatic individuals","volume":"10","author":"Shastri","year":"2015","journal-title":"PLoS One"},{"issue":"04","key":"10.1016\/j.biopha.2021.111561_bib130","first-page":"258","article-title":"Research progress of nebulized heparin for acute lung injury","volume":"52","author":"Hu","year":"2017","journal-title":"Chin. Pharm. J."},{"issue":"22","key":"10.1016\/j.biopha.2021.111561_bib131","doi-asserted-by":"crossref","first-page":"444","DOI":"10.21037\/atm.2017.08.23","article-title":"Nebulized anticoagulants in lung injury in critically ill patients-an updated systematic review of preclinical and clinical studies","volume":"5","author":"Juschten","year":"2017","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib132","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13613-016-0138-4","article-title":"Nebulized heparin for patients under mechanical ventilation: an individual patient data meta-analysis","volume":"6","author":"Glas","year":"2016","journal-title":"Ann. Intensive Care"},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib133","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/cc9269","article-title":"Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury","volume":"14","author":"Dixon","year":"2010","journal-title":"Crit. Care"},{"issue":"7","key":"10.1016\/j.biopha.2021.111561_bib134","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1007\/s00134-008-1042-7","article-title":"Elevated pulmonary dead space and coagulation abnormalities suggest lung microvascular thrombosis in patients undergoing cardiac surgery","volume":"34","author":"Dixon","year":"2008","journal-title":"Intensive Care Med."},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib135","doi-asserted-by":"crossref","first-page":"R180","DOI":"10.1186\/cc9286","article-title":"Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial","volume":"14","author":"Dixon","year":"2010","journal-title":"Crit. Care"},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib136","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0310057X1604400106","article-title":"A trial of nebulised heparin to limit lung injury following cardiac surgery","volume":"44","author":"Dixon","year":"2016","journal-title":"Anaesth. Intensive Care"},{"issue":"4","key":"10.1016\/j.biopha.2021.111561_bib137","first-page":"339","article-title":"Heparin improves oxygenation and minimizes barotrauma after severe smoke inhalation in an ovine model","volume":"176","author":"Cox","year":"1993","journal-title":"Surg. Gynecol. Obstet."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib138","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00004630-198801000-00007","article-title":"Dimethylsulfoxide with heparin in the treatment of smoke inhalation injury","volume":"9","author":"Brown","year":"1988","journal-title":"J. Burn Care Rehabil."},{"issue":"10","key":"10.1016\/j.biopha.2021.111561_bib139","first-page":"612","article-title":"The effects of three dosages of nebulized unfractionated heparin on alveolar coagulation and tissue inflammation injury in endotoxin-induced acute lung injury rat model","volume":"24","author":"Wang","year":"2012","journal-title":"Zhongguo wei zhong bing ji jiu yi xue"},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib140","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/01.CCM.0000201882.23917.B8","article-title":"Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia--a review","volume":"34","author":"Schultz","year":"2006","journal-title":"Crit. Care Med."},{"issue":"029","key":"10.1016\/j.biopha.2021.111561_bib141","first-page":"36","article-title":"Efficacy of low molecular weight heparin combined with acetylcysteine in the treatment of idiopathic interstitial pneumonia","volume":"5","author":"Hu","year":"2017","journal-title":"Cardiovasc. Dis. Electron. J. Integr. Tradit. Chin. West. Med."},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib142","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3892\/etm.2013.1001","article-title":"Anticoagulation therapy in patients with chronic obstructive pulmonary disease in the acute exacerbation stage","volume":"5","author":"Shi","year":"2013","journal-title":"Exp. Ther. Med."},{"issue":"01","key":"10.1016\/j.biopha.2021.111561_bib143","first-page":"18","article-title":"Observation of the therapeutic effect of low molecular weight heparin on AECOPD","volume":"25","author":"Sun","year":"2020","journal-title":"Zhejiang Pract. Med."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib144","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/jamp.2015.1273","article-title":"Inhaled heparin: therapeutic efficacy and recent formulations","volume":"30","author":"Yildiz-Pekoz","year":"2017","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib145","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ki.2014.260","article-title":"A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment","volume":"87","author":"Yoshikawa","year":"2015","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib146","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/ki.2014.240","article-title":"Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome","volume":"87","author":"Sinha","year":"2015","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib147","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10157-014-0996-8","article-title":"Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study","volume":"19","author":"Muso","year":"2015","journal-title":"Clin. Exp. Nephrol."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib148","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2215\/CJN.07190713","article-title":"Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"issue":"03","key":"10.1016\/j.biopha.2021.111561_bib149","first-page":"32","article-title":"Effect of low molecular weight heparin on coagulation indexes, biochemical indexes and clinical efficacy of patients with nephrotic syndrome","volume":"21","author":"Sun","year":"2017","journal-title":"J. Clin. Med. Pract."},{"issue":"21","key":"10.1016\/j.biopha.2021.111561_bib150","first-page":"1327","article-title":"The protective effect of low molecular weight heparin on early nephropathy in diabetic rats","volume":"81","author":"Guo","year":"2001","journal-title":"Zhonghua yi xue za zhi"},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdiacomp.2007.09.006","article-title":"Factors affecting hospitalization costs in type 2 diabetic patients","volume":"23","author":"Pagano","year":"2009","journal-title":"J. Diabetes Complicat."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib152","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00125-012-2796-6","article-title":"Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: a meta-analysis","volume":"56","author":"He","year":"2013","journal-title":"Diabetologia"},{"issue":"Suppl. 2","key":"10.1016\/j.biopha.2021.111561_bib153","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.2337\/dc08-s251","article-title":"Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin","volume":"31","author":"Lewis","year":"2008","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.biopha.2021.111561_bib154","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.2337\/db12-1512","article-title":"Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes","volume":"62","author":"Weil","year":"2013","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.biopha.2021.111561_bib155","first-page":"119","article-title":"Anticoagulant effect of low molecular weight heparin in hemodialysis treatment of acute renal failure","volume":"14","author":"Cao","year":"2019","journal-title":"China Pract. Med."},{"issue":"022","key":"10.1016\/j.biopha.2021.111561_bib156","first-page":"116","article-title":"Effect of low molecular weight heparin on lipid metabolism in maintenance hemodialysis patients","volume":"6","author":"Zuo","year":"2016","journal-title":"Med. Front."},{"issue":"32","key":"10.1016\/j.biopha.2021.111561_bib157","first-page":"3562","article-title":"Observation of curative effect of Fushen decoction combined with low molecular weight heparin on nephritis with anaphylactic purpura of heat-wet stasis syndrome in children","volume":"25","author":"Tian","year":"2016","journal-title":"Mod. J. Integr. Tradit. Chin. West. Med."},{"issue":"12","key":"10.1016\/j.biopha.2021.111561_bib158","first-page":"2269","article-title":"Clinical analysis of low molecular weight heparin combined with danshen injection in children with henoch sehonlein purpura nephritis","volume":"20","author":"Qiu","year":"2014","journal-title":"Med. Recapitul."},{"key":"10.1016\/j.biopha.2021.111561_bib159","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ijgo.13266","article-title":"Meta-analysis of heparin combined with aspirin versus aspirin alone for unexplained recurrent spontaneous abortion","volume":"151","author":"Li","year":"2020","journal-title":"Int. J. Gynecol. Obstet."},{"issue":"8","key":"10.1016\/j.biopha.2021.111561_bib160","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520945558","article-title":"Role of low-molecular-weight heparin in altering uterine artery blood flow in recurrent spontaneous abortion: a prospective study","volume":"48","author":"Zhang","year":"2020","journal-title":"J. Int. Med. Res."},{"issue":"08","key":"10.1016\/j.biopha.2021.111561_bib161","first-page":"631","article-title":"Research progress of low molecular weight heparin in obstetrics","volume":"25","author":"Yuan","year":"2016","journal-title":"Prog. Obstet. Gynecol."},{"key":"10.1016\/j.biopha.2021.111561_bib162","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.thromres.2015.11.026","article-title":"Microvesicles of pregnant women receiving low molecular weight heparin improve trophoblast function","volume":"137","author":"Shomer","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.biopha.2021.111561_bib163","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/aji.12348","article-title":"Low molecular weight heparin modulates maternal immune response in pregnant women and mice with thrombophilia","author":"Luley","year":"2015","journal-title":"Am. J. Reprod. Immunol."},{"issue":"13","key":"10.1016\/j.biopha.2021.111561_bib164","first-page":"2202","article-title":"Prevention of preeclampsia in high-risk patients with low-molecular-weight heparin: a meta-analysis","volume":"33","author":"Wang","year":"2020","journal-title":"J. Matern.-Fetal Neonatal Med. Off. J. Eur. Assoc. Perinat. Med. Fed. Asia Ocean. Perinat. Soc. Int. Soc. Perinat. Obstet."},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib165","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/uog.15789","article-title":"Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis","volume":"47","author":"Roberge","year":"2016","journal-title":"Ultrasound Obstet. Gynecol. Off. J. Int. Soc. Ultrasound Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib166","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/HYPERTENSIONAHA.116.08298","article-title":"Low molecular weight heparin improves endothelial function in pregnant women at high risk of preeclampsia","volume":"69","author":"McLaughlin","year":"2017","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.biopha.2021.111561_bib167","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/HYPERTENSIONAHA.115.05770","article-title":"Current theories on the prevention of severe preeclampsia with low-molecular weight heparin","volume":"66","author":"McLaughlin","year":"2015","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.biopha.2021.111561_bib168","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2013-01-478958","article-title":"Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications","volume":"123","author":"Rodger","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib169","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/AOG.0000000000002380","article-title":"Angiogenic factor profiles in pregnant women with a history of early-onset severe preeclampsia receiving low-molecular-weight heparin prophylaxis","volume":"131","author":"Lecarpentier","year":"2018","journal-title":"Obstet. Gynecol."},{"issue":"01","key":"10.1016\/j.biopha.2021.111561_bib170","first-page":"164","article-title":"Clinical observation of low molecular weight heparin in the treatment of abnormal umbilical artery blood flow in the second and third trimester of pregnancy","volume":"28","author":"Li","year":"2018","journal-title":"Shenzhen J. Integr. Tradit. Chin. West. Med."},{"issue":"02","key":"10.1016\/j.biopha.2021.111561_bib171","first-page":"272","article-title":"Curative effect of low molecular weight heparin combined with magnesium sulfate in treatment of preeclampsia and the influence on HtrA4 and Syncytin-1 levels in maternal blood and placenta","volume":"33","author":"Ma","year":"2018","journal-title":"Matern. Child Health Care China"},{"issue":"03","key":"10.1016\/j.biopha.2021.111561_bib172","first-page":"691","article-title":"Clinical efficacy of aspirin combined with low molecular weight heparin in the treatment of fetal growth restriction and its influence on fetal blood flow parameters and maternal and infant outcomes","volume":"25","author":"Chen","year":"2019","journal-title":"Hebei Med."},{"issue":"02","key":"10.1016\/j.biopha.2021.111561_bib173","first-page":"145","article-title":"Clinical effect and safety of low molecular weight heparin in the treatment of oligohydramnios in late pregnancy","volume":"18","author":"Guo","year":"2020","journal-title":"J. Bethune Med. Sci."},{"issue":"22","key":"10.1016\/j.biopha.2021.111561_bib174","first-page":"3687","article-title":"Clinical observation of low molecular weight heparin in the treatment of 45 cases of intrahepatic cholestasis of pregnancy","volume":"32","author":"Liu","year":"2019","journal-title":"J. Med. Theory Pract."},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib175","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.clinre.2012.12.006","article-title":"Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: good, but can do better","volume":"37","author":"Erlinger","year":"2013","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"Suppl. 2","key":"10.1016\/j.biopha.2021.111561_bib176","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/S0049-3848(14)50023-0","article-title":"Heparins and cancer survival: where do we stand?","volume":"133","author":"Noble","year":"2014","journal-title":"Thromb. Res."},{"issue":"12","key":"10.1016\/j.biopha.2021.111561_bib177","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.bbadis.2011.09.007","article-title":"Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-\u03baB","volume":"1812","author":"Ettelaie","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2021.111561_bib178","first-page":"121","article-title":"Dose-reduction antiangiogenic curcumin-low molecular weight heparin nanodrugs for enhanced combinational antitumor therapy","volume":"119","author":"Xiao","year":"2018","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2021.111561_bib179","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0006-2952(85)90588-X","article-title":"Regulation of angiogenesis: a new function of heparin","volume":"34","author":"Folkman","year":"1985","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2021.111561_bib180","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.abb.2016.06.018","article-title":"Role of heparin and non heparin binding serpins in coagulation and angiogenesis: a complex interplay","volume":"604","author":"Bhakuni","year":"2016","journal-title":"Arch. Biochem. Biophys."},{"issue":"Suppl. 1","key":"10.1016\/j.biopha.2021.111561_bib181","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1016\/j.thromres.2017.12.011","article-title":"Novel strategies of coagulation inhibition for reducing tumor growth and angiogenesis","volume":"164","author":"Nadir","year":"2018","journal-title":"Thromb. Res."},{"issue":"11","key":"10.1016\/j.biopha.2021.111561_bib182","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.exphem.2016.08.006","article-title":"Mechanisms of heparanase inhibitors in cancer therapy","volume":"44","author":"Heyman","year":"2016","journal-title":"Exp. Hematol."},{"issue":"3\u20134","key":"10.1016\/j.biopha.2021.111561_bib183","first-page":"195","article-title":"Non-anticoagulant heparins and inhibition of cancer","volume":"36","author":"Casu","year":"2008","journal-title":"Pathophysiol. Haemost. Thromb."},{"issue":"03","key":"10.1016\/j.biopha.2021.111561_bib184","first-page":"273","article-title":"Effect of low molecular weight heparin on hypercoagulability and survival rate in patients with malignant tumor","volume":"15","author":"Ye","year":"2016","journal-title":"Chin. J. Diffic. Complicat. Cases"},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib185","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.arthro.2013.12.021","article-title":"Deep venous thrombosis after knee arthroscopy: a systematic review and meta-analysis","volume":"30","author":"Sun","year":"2014","journal-title":"Arthrosc. J. Arthrosc. Relat. Surg. Off. Publ. Arthrosc. Assoc. N. Am. Int. Arthrosc. Assoc."},{"issue":"Suppl. 1","key":"10.1016\/j.biopha.2021.111561_bib186","doi-asserted-by":"crossref","first-page":"132s","DOI":"10.1378\/chest.119.1_suppl.132S","article-title":"Prevention of venous thromboembolism","volume":"119","author":"Geerts","year":"2001","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib187","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/jth.14810","article-title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19","volume":"18","author":"Thachil","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib188","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s13054-020-03148-2","article-title":"Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence","volume":"24","author":"van Haren","year":"2020","journal-title":"Crit. Care"},{"issue":"10223","key":"10.1016\/j.biopha.2021.111561_bib189","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib190","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/22221751.2020.1746199","article-title":"Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia","volume":"9","author":"Lin","year":"2020","journal-title":"Emerg. Microbes Infect."},{"issue":"23","key":"10.1016\/j.biopha.2021.111561_bib191","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","article-title":"COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review","volume":"75","author":"Bikdeli","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2021.111561_bib192","unstructured":"Consensus on novel coronavirus pneumonia in extracorporeal membrane oxygenation support therapy, Chin. J. Emerg. Med., 29(03), 2020, pp. 314\u2013319."},{"issue":"09","key":"10.1016\/j.biopha.2021.111561_bib193","first-page":"1715","article-title":"Comparative study on efficacy and influence on blood coagulation between low molecular weight heparin and unfractionated heparin in the treatment of elderly patients with severe pneumonia","volume":"20","author":"Liang","year":"2015","journal-title":"J. Clin. Pulm. Med."},{"key":"10.1016\/j.biopha.2021.111561_bib194","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coph.2019.03.009","article-title":"The non-anticoagulant promise of heparin and its mimetics","volume":"46","author":"Mulloy","year":"2019","journal-title":"Curr. Opin. Pharmacol."},{"issue":"11","key":"10.1016\/j.biopha.2021.111561_bib195","first-page":"2104","article-title":"In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19","volume":"33","author":"Schaefer","year":"2020","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib196","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12931-017-0572-3","article-title":"Role of heparin in pulmonary cell populations in an in-vitro model of acute lung injury","volume":"18","author":"Camprub\u00ed-Rimblas","year":"2017","journal-title":"Respir. Res."},{"issue":"8","key":"10.1016\/j.biopha.2021.111561_bib197","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023710","article-title":"Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans","volume":"6","author":"Lang","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.biopha.2021.111561_bib198","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2021.111561_bib199","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104873","article-title":"Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions","volume":"181","author":"Kim","year":"2020","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib200","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bph.15304","article-title":"Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations","volume":"178","author":"Tree","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2021.111561_bib201","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijbiomac.2013.01.014","article-title":"Synthesized negatively charged macromolecules (NCMs) for the surface modification of anticoagulant membrane biomaterials","volume":"55","author":"Ran","year":"2013","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biopha.2021.111561_bib202","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.addr.2016.12.002","article-title":"Heparin coatings for improving blood compatibility of medical devices","volume":"112","author":"Biran","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2021.111561_bib203","unstructured":"C. Chen, The Preparation and Blood Compatibility Properties of Heparin-Like Hyper-Branched Polyimide, 2011."},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib204","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00216-010-4272-9","article-title":"The use of circular dichroism as a simple heparin-screening strategy","volume":"399","author":"Stanley","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.biopha.2021.111561_bib205","series-title":"New Chemical Materials","first-page":"3","article-title":"Heparinization of polymers","author":"Tan","year":"1998"},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib206","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm.3073","article-title":"Malaria biology and disease pathogenesis: insights for new treatments","volume":"19","author":"Miller","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib207","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/523762","article-title":"Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria","volume":"197","author":"Dondorp","year":"2008","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib208","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1538-7836.2006.02232.x","article-title":"Plasmodium falciparum-infected erythrocytes induce tissue factor expression in endothelial cells and support the assembly of multimolecular coagulation complexes","volume":"5","author":"Francischetti","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.biopha.2021.111561_bib209","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1086\/528988","article-title":"Rho kinase inhibition in severe malaria: thwarting parasite-induced collateral damage to endothelia","volume":"197","author":"Taoufiq","year":"2008","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172718","article-title":"Effects of sevuparin on rosette formation and cytoadherence of Plasmodium falciparum infected erythrocytes","volume":"12","author":"Saiwaew","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib211","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.290.2.238","article-title":"Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial","volume":"290","author":"Abraham","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib212","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.14885","article-title":"The role of heparin in sepsis: much more than just an anticoagulant","volume":"179","author":"Li","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2021.111561_bib213","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jss.2019.01.020","article-title":"Unfractionated heparin alleviates sepsis-induced acute lung injury by protecting tight junctions","volume":"238","author":"Liu","year":"2019","journal-title":"J. Surg. Res."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib214","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/TA.0000000000002387","article-title":"Unfractionated heparin attenuates histone-mediated cytotoxicity in vitro and prevents intestinal microcirculatory dysfunction in histone-infused rats","volume":"87","author":"Zhu","year":"2019","journal-title":"J. Trauma Acute Care Surg."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib215","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/CCM.0000000000000763","article-title":"The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis","volume":"43","author":"Zarychanski","year":"2015","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.biopha.2021.111561_bib216","doi-asserted-by":"crossref","first-page":"25984","DOI":"10.1038\/srep25984","article-title":"Efficacy and safety of low-molecular-weight heparin in patients with sepsis: a meta-analysis of randomized controlled trials","volume":"6","author":"Fan","year":"2016","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.biopha.2021.111561_bib217","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/ibd.21221","article-title":"Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts","volume":"16","author":"Jharap","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"issue":"7","key":"10.1016\/j.biopha.2021.111561_bib218","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1046\/j.1365-2036.2002.01297.x","article-title":"Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine","volume":"16","author":"Fraser","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib219","doi-asserted-by":"crossref","first-page":"G514","DOI":"10.1152\/ajpgi.90608.2008","article-title":"Cyclosporine regulates intestinal epithelial apoptosis via TGF-beta-related signaling","volume":"297","author":"Satoh","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.biopha.2021.111561_bib220","first-page":"1027","article-title":"Research progress on pharmacological action of low molecular weight heparin","volume":"05","author":"Ma","year":"2008","journal-title":"Chin. J. Misdiagn."},{"issue":"05","key":"10.1016\/j.biopha.2021.111561_bib221","first-page":"51","article-title":"Effect of low molecular weight heparin in reducing serum TG and treating hyperlipidemic mild acute pancreatitis","volume":"54","author":"Xu","year":"2014","journal-title":"Shandong Med. J."},{"issue":"14","key":"10.1016\/j.biopha.2021.111561_bib222","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2146\/ajhp120096","article-title":"Subcutaneous heparin for treatment of hypertriglyceridemia-induced pancreatitis","volume":"69","author":"Cheema","year":"2012","journal-title":"Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib223","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10620-005-9006-z","article-title":"Heparin and insulin in the treatment of hypertriglyceridemia-induced severe acute pancreatitis","volume":"51","author":"Alag\u00f6zl\u00fc","year":"2006","journal-title":"Dig. Dis. Sci."},{"issue":"16","key":"10.1016\/j.biopha.2021.111561_bib224","first-page":"2727","article-title":"Clinical observation of low molecular weight heparin combined with alprostadil in the treatment of hyperlipidemic acute pancreatitis","volume":"29","author":"Lin","year":"2013","journal-title":"J. Pract. Med."},{"issue":"5","key":"10.1016\/j.biopha.2021.111561_bib225","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2125.2010.03626.x","article-title":"Current dosing of low-molecular-weight heparins does not reflect licensed product labels: an international survey","volume":"69","author":"Barras","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib226","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00228-010-0956-5","article-title":"Drug use problems with self-injected low-molecular-weight heparins in primary care","volume":"67","author":"Mengiardi","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111561_bib227","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1365-2648.2001.01925.x","article-title":"Effects of injection duration on site-pain intensity and bruising associated with subcutaneous heparin","volume":"35","author":"Chan","year":"2001","journal-title":"J. Adv. Nurs."},{"issue":"6","key":"10.1016\/j.biopha.2021.111561_bib228","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.ijnurstu.2007.02.005","article-title":"Effect of injection duration on bruising associated with subcutaneous heparin: a quasi-experimental within-subject design","volume":"45","author":"Balci Akpinar","year":"2008","journal-title":"Int. J. Nurs. Stud."},{"issue":"4","key":"10.1016\/j.biopha.2021.111561_bib229","article-title":"Subcutaneous administration technique of low-molecular-weight heparins: an integrative review","volume":"1","author":"Campos","year":"2013","journal-title":"Clin. Nurs. Stud."},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib230","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1053\/j.ajkd.2009.03.012","article-title":"Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis","volume":"54","author":"Davenport","year":"2009","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"issue":"983","key":"10.1016\/j.biopha.2021.111561_bib231","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/pgmj.2007.059188","article-title":"Heparin induced thrombocytopenia: diagnosis and management update","volume":"83","author":"Ahmed","year":"2007","journal-title":"Postgrad. Med. J."},{"issue":"2","key":"10.1016\/j.biopha.2021.111561_bib232","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1055\/s-0037-1612970","article-title":"Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin","volume":"87","author":"Pettil\u00e4","year":"2002","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.biopha.2021.111561_bib233","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.thromres.2006.10.025","article-title":"The effects of heparin and low molecular weight heparins on bone","volume":"122","author":"Rajgopal","year":"2008","journal-title":"Thromb. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.biopha.2021.111561_bib234","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0961203309353171","article-title":"Review: low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity?","volume":"19","author":"Lefkou","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.biopha.2021.111561_bib236","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bone.2015.04.039","article-title":"Heparin affects human bone marrow stromal cell fate: promoting osteogenic and reducing adipogenic differentiation and conversion","volume":"78","author":"Simann","year":"2015","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.biopha.2021.111561_bib237","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3390\/ijms17040613","article-title":"Unfractionated heparin promotes osteoclast formation in vitro by inhibiting osteoprotegerin activity","volume":"17","author":"Li","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2021.111561_bib238","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s11606-016-3603-8","article-title":"Effects of long-term low-molecular-weight heparin on fractures and bone density in non-pregnant adults: a systematic review with meta-analysis","volume":"31","author":"Gajic-Veljanoski","year":"2016","journal-title":"J. Gen. Intern. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.111561_bib239","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaci.2013.02.047","article-title":"High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy","volume":"132","author":"Schindewolf","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"06","key":"10.1016\/j.biopha.2021.111561_bib240","first-page":"573","article-title":"Research progress on pharmacological action and clinical application of low molecular weight heparin","volume":"21","author":"Liu","year":"2014","journal-title":"Pharm. Biotechnol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221003462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221003462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:19:59Z","timestamp":1760098799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221003462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":240,"alternative-id":["S0753332221003462"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111561","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological and clinical application of heparin progress: An essential drug for modern medicine","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111561","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111561"}}